Business
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif., November 10, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for the company’s ongoing pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical tri
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/1255bbc7ff66855540a1963f101a1e42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V.8eZMjBkupZfLiaM5d_Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1255bbc7ff66855540a1963f101a1e42","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/e.Ro6KWVjQWWhBdiV.iuKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/1255bbc7ff66855540a1963f101a1e42","width":1121,"height":442}},"lazy":false},{"type":"text","content":"No safety concerns identified by independent data and safety monitoring board, which recommends continuation of study without any modifications","length":143,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., November 10, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for the company’s ongoing pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia (A-T). The iDSMB recommended that the study continue without any modifications.","length":709,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "The positive outcome from our recent iDSMB review of eDSP reaffirms our confidence in the favorable safety profile of eDSP to date. As we continue to advance eDSP as a potential first-to-market A-T treatment, we are pleased that no safety concerns have been identified as our pivotal Phase 3 NEAT study progresses. We remain on track to report topline results from the study in the first quarter of 2026."","length":499,"tagName":"p"},{"type":"text","content":"Quince’s pivotal Phase 3 NEAT study is an international, multicenter, randomized, double-blind...